REG - ValiRx PLC - Result of GM & Issue of Equity
20/11/2025 12:15
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251120:nRST3996Ia&default-theme=true
RNS Number : 3996I ValiRx PLC 20 November 2025
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET
ABUSE REGULATION (EU) 596/2014 AS AMENDED BY REGULATION 11 OF THE MARKET ABUSE
(AMENDMENT) (EU EXIT) REGULATIONS 2019/310. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS
NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
20 November 2025
VALIRX PLC
("ValiRx" or the "Company")
Result of General Meeting
Issue of Equity and Total Voting Rights
Director and PDMR Shareholding
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, announces that, further to
the announcement on 4 November 2025, at the Company's General Meeting held
earlier today, all resolutions were duly passed. Details of the votes received
in respect of the resolutions will be available shortly on the Company's
website.
Issue of Equity
The Tranche 2 Placing Shares, the Subscription Shares, the Fee Shares and the
WRAP Retail Offer Shares have been allotted, conditional upon Admission, and
application has been made to the London Stock Exchange for, in aggregate,
256,067,800 Shares to be admitted to trading on AIM. Admission is expected to
occur at 8.00 a.m. on 21 November 2025, with dealings in the Tranche 2 Placing
Shares, the Subscription Shares, the Fee Shares and the WRAP Retail Offer
Shares commencing at the same time. The Tranche 2 Placing Shares, the
Subscription Shares, the Fee Shares and the WRAP Retail Offer Shares will rank
pari passu with all other issued Shares.
Issue of Warrants
Pursuant to the Fundraising and in connection with the issuance of the Fee
Shares the Company has issued 368,372,400 Fundraising Warrants. The
Fundraising Warrants will be exercisable at a price of 0.5 pence per Ordinary
Share and are exercisable at any time until the third anniversary of Tranche 2
Admission.
In addition, the Company has issued 16,036,120 Broker Warrants. The Broker
Warrants will be exercisable at the Issue Price. The Broker Warrants are
exercisable at any time until the third anniversary of Tranche 2 Admission.
Director and PDMR Shareholdings
Following completion of the Fundraising, the shareholdings of the Directors
who participated in the Fundraising are set out in the table below:
( )
Name Number of existing Ordinary Shares Percentage of existing issued share capital Number of New Ordinary Shares Number of Ordinary Shares on Tranche 2 Admission Percentage of enlarged share capital on Tranche 2 Admission
Mark Eccleston 22,746,187 6.08% 36,000,000 58,746,187 7.91%
Cathy Tralau-Stewart 835,897 0.22% 1,200,000 2,035,897 0.27%
Gerry Desler 964,565 0.26% 1,200,000 2,164,565 0.29%
Martin Gouldstone 769,231 0.21% 1,200,000 1,969,231 0.27%
Total 25,315,880 6.76% 39,600,000 64,915,880 8.74%
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
742,721,072 ordinary shares of 0.1 pence each. The Company does not hold any
shares in the treasury. The above figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company, under the Disclosure Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in
the Circular dated 4 November 2025, unless otherwise defined in this
announcement.
The Directors of the Company take responsibility for this announcement.
For more information, please contact:
Investor questions on this announcement https://valirx.com/link/yEMZvy
We encourage all investors to share questions
on this announcement via our investor hub
ValiRx plc Tel: +44 115 784 0026
www.valirx.com (http://www.valirx.com)
Dr Mark Eccleston, CEO Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0) 20 7213 0880
Liam Murray / Ludovico Lazzaretti
Shard Capital Partners LLP (Broker) Tel: +44 (0) 20 7186 9000
Damon Heath
Andrew Gutmann
SP Angel Corporate Finance LLP (Placing Agent) Tel: +44 (0) 20 3470 0470
David Hignell
Vadim Alexandre
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz (http://www.vformation.biz)
Lucy Wharton - Senior PR Executive lucy@vformation.biz
Sue Carr - Director sue@vformation.biz
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name A) Mark Eccleston
B) Cathy Tralau-Stewart
C) Gerry Desler
D) Martin Gouldstone
2 Reason for notification
a. Position/Status A) Director
B) Director
C) Director
D) Director
b. Initial notification/ Initial notification
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name ValiRx PLC
b. LEI 213800VQKB9SJCQDET40
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary Shares
Identification Code
ISIN: GB00BLH13C52
b. Nature of the transaction Purchase of shares as part of the Fundraising
c. Price(s) and volume(s)
Price(s) Volume(s)
A) 0.25 pence 36,000,000
B) 0.25 pence 1,200,000
C) 0.25 pence 1,200,000
D) 0.25 pence 1,200,000
d. Aggregated information
- Aggregated Volume N/A
- Price
e. Date of the transaction 20 November 2025
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name A) Mark Eccleston
B) Cathy Tralau-Stewart
C) Gerry Desler
D) Martin Gouldstone
2 Reason for notification
a. Position/Status A) Director
B) Director
C) Director
D) Director
b. Initial notification/ Initial notification
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name ValiRx PLC
b. LEI 213800VQKB9SJCQDET40
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Warrants over new Ordinary Shares exercisable at a price of 0.5 pence per
share
Identification Code
ISIN: GB00BLH13C52
b. Nature of the transaction Warrants as part of the Fundraising
c. Price(s) and volume(s)
Price(s) Volume(s)
A) 0.5 pence 36,000,000
B) 0.5 pence 1,200,000
C) 0.5 pence 1,200,000
D) 0.5 pence 1,200,000
d. Aggregated information
- Aggregated Volume N/A
- Price
e. Date of the transaction 20 November 2025
f. Place of the transaction Outside a trading venue
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com (http://www.valirx.com/)
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
and reading this announcement should not place undue reliance on
forward-looking statements. Unless otherwise required by applicable law,
regulation or accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new information,
future developments or otherwise.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ROMBMBTTMTMTBFA
Copyright 2019 Regulatory News Service, all rights reservedRecent news on ValiRx
See all newsREG - ValiRx PLC - Holding(s) in Company
AnnouncementREG - ValiRx PLC - Holding(s) in Company
AnnouncementREG - ValiRx PLC - Holding(s) in Company
AnnouncementREG - AIM - AIM Notice - 21/11/2025
AnnouncementREG - ValiRx PLC - Result of GM & Issue of Equity
Announcement